NASDAQHealth CareBiotechnologySnapshot 2026-07-23
Reading SEER? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a speculative growth opportunity. SEER is currently navigating a loss-making phase while aiming for revenue growth amidst sector tailwinds.
The market appears to have priced in a low level of fragility, indicating that current valuations are justified. SEER is seen as cheap compared to its peers, but there is a notable expectations gap.
Management is focused on achieving revenue targets and maintaining gross profit margins, though recent performance has been mixed. There is a risk of missing guidance, especially given the high miss probability in the industry.
The thesis hinges on the performance of sector bellwethers and SEER's ability to meet its revenue guidance. Any guidance cuts or misses could negatively impact sentiment, while strong results from peers could provide support.
In the next 1 to 3 years, SEER's trajectory will depend on its execution against revenue goals and the broader healthcare sector's performance. Not investment advice.
The most important moves since the prior daily snapshot.
No, our read on the company is unchanged. There are no new strengths or weaknesses. The market backdrop has shifted slightly, but it does not affect the thesis. Overall, the situation remains steady for SEER.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: The earnings report will provide insights into revenue and profit trends.
Confirms one read:Earnings report shows revenue growth and improved margins.
Confirms the other:Earnings report shows revenue decline and worsening margins.
Why it matters: The company aims for $16M to $18M in revenue for 2026. A revision could signal issues.
Confirms:Q2 revenue guidance remains within the $16M to $18M range.
Disproves:Q2 revenue guidance is revised down from the $16M to $18M range.
Why it matters: Maintaining gross margin is key for financial health. A drop could indicate deeper issues.
Confirms:Gross margin remains above 30% for Q2.
Disproves:Gross margin falls below 30% in Q2.
Why it matters: Reaching close to $4M in Q2 shows progress toward the $16M-$18M goal for 2026.
Confirms:Q2 revenue reported at $4M or higher.
Disproves:Q2 revenue reported below $3M.
Why it matters: If the healthcare sector's revenue growth speeds up, it could benefit Seer Inc. as well. It shows a healthier market environment.
Confirms:Healthcare sector revenue growth rises above 10% year over year.
Disproves:Healthcare sector revenue growth remains below 10% year over year.
Why it matters: Missing earnings often means there are bigger problems in the business.
Confirms:The next earnings report shows a miss on revenue or profit.
Disproves:Earnings report meets or beats expectations.
Why it matters: This partnership could prove Seer's technology. It may also increase future revenue.
Confirms:Look for publications or results from the partnership.
Disproves:No updates or results are shared by the end of Q3.
Why it matters: The Board's choice on the acquisition plan could change stockholder value and market views.
Confirms one read:The Board accepts the proposal or presents a counter-offer.
Confirms the other:The Board strongly rejects the proposal. There will be no further talks.
